These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I. Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037 [TBL] [Abstract][Full Text] [Related]
23. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor. Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561 [TBL] [Abstract][Full Text] [Related]
24. Discovery of new orally active phosphodiesterase (PDE4) inhibitors. Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197 [TBL] [Abstract][Full Text] [Related]
25. Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor. Hersperger R; Dawson J; Mueller T Bioorg Med Chem Lett; 2002 Jan; 12(2):233-5. PubMed ID: 11755362 [TBL] [Abstract][Full Text] [Related]
26. N-arylrolipram derivatives as potent and selective PDE4 inhibitors. Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708 [TBL] [Abstract][Full Text] [Related]
27. New orally active PDE4 inhibitors with therapeutic potential. Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Obata T; Nakai H; Toda M Bioorg Med Chem Lett; 2004 Jan; 14(1):29-32. PubMed ID: 14684291 [TBL] [Abstract][Full Text] [Related]
28. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters. Frenette R; Blouin M; Brideau C; Chauret N; Ducharme Y; Friesen RW; Hamel P; Jones TR; Laliberté F; Li C; Masson P; McAuliffe M; Girard Y Bioorg Med Chem Lett; 2002 Oct; 12(20):3009-13. PubMed ID: 12270195 [TBL] [Abstract][Full Text] [Related]
29. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. Man HW; Schafer P; Wong LM; Patterson RT; Corral LG; Raymon H; Blease K; Leisten J; Shirley MA; Tang Y; Babusis DM; Chen R; Stirling D; Muller GW J Med Chem; 2009 Mar; 52(6):1522-4. PubMed ID: 19256507 [TBL] [Abstract][Full Text] [Related]
30. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647 [TBL] [Abstract][Full Text] [Related]
31. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one. Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802 [TBL] [Abstract][Full Text] [Related]
32. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors. Regan J; Bruno J; McGarry D; Poli G; Hanney B; Bower S; Travis J; Sweeney D; Miller B; Souness J; Djuric S Bioorg Med Chem Lett; 1998 Oct; 8(19):2737-42. PubMed ID: 9873613 [TBL] [Abstract][Full Text] [Related]
33. Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams. Hulme C; Moriarty K; Huang FC; Mason J; McGarry D; Labaudiniere R; Souness J; Djuric S Bioorg Med Chem Lett; 1998 Feb; 8(4):399-404. PubMed ID: 9871693 [TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. Draheim R; Egerland U; Rundfeldt C J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230 [TBL] [Abstract][Full Text] [Related]
35. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Hulme C; Moriarty K; Miller B; Mathew R; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Huang FC; Labaudiniere R; Djuric SW Bioorg Med Chem Lett; 1998 Jul; 8(14):1867-72. PubMed ID: 9873449 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones. Gouault N; Pinel B; Cupif JF; Depince A; Martin-Chouly CA; Belleguic C; David M J Enzyme Inhib Med Chem; 2004 Dec; 19(6):475-80. PubMed ID: 15662951 [TBL] [Abstract][Full Text] [Related]
39. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma. Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830 [TBL] [Abstract][Full Text] [Related]
40. Differential modulation of cytokine production by drugs: implications for therapy in heart failure. Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]